These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

610 related items for PubMed ID: 22068070

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Successful treatment of catecholaminergic polymorphic ventricular tachycardia with flecainide: a case report and review of the current literature.
    Pott C, Dechering DG, Reinke F, Muszynski A, Zellerhoff S, Bittner A, Köbe J, Wasmer K, Schulze-Bahr E, Mönnig G, Kotthoff S, Eckardt L.
    Europace; 2011 Jun; 13(6):897-901. PubMed ID: 21292648
    [Abstract] [Full Text] [Related]

  • 6. Incidence and risk factors of arrhythmic events in catecholaminergic polymorphic ventricular tachycardia.
    Hayashi M, Denjoy I, Extramiana F, Maltret A, Buisson NR, Lupoglazoff JM, Klug D, Hayashi M, Takatsuki S, Villain E, Kamblock J, Messali A, Guicheney P, Lunardi J, Leenhardt A.
    Circulation; 2009 May 12; 119(18):2426-34. PubMed ID: 19398665
    [Abstract] [Full Text] [Related]

  • 7. Guidelines for the diagnosis and management of Catecholaminergic Polymorphic Ventricular Tachycardia.
    Pflaumer A, Davis AM.
    Heart Lung Circ; 2012 Feb 12; 21(2):96-100. PubMed ID: 22119737
    [Abstract] [Full Text] [Related]

  • 8. Co-Phenotype of Left Ventricular Non-Compaction Cardiomyopathy and Atypical Catecholaminergic Polymorphic Ventricular Tachycardia in Association With R169Q, a Ryanodine Receptor Type 2 Missense Mutation.
    Nozaki Y, Kato Y, Uike K, Yamamura K, Kikuchi M, Yasuda M, Ohno S, Horie M, Murayama T, Kurebayashi N, Horigome H.
    Circ J; 2020 Jan 24; 84(2):226-234. PubMed ID: 31875585
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Arrhythmia characterization and long-term outcomes in catecholaminergic polymorphic ventricular tachycardia.
    Sy RW, Gollob MH, Klein GJ, Yee R, Skanes AC, Gula LJ, Leong-Sit P, Gow RM, Green MS, Birnie DH, Krahn AD.
    Heart Rhythm; 2011 Jun 24; 8(6):864-71. PubMed ID: 21315846
    [Abstract] [Full Text] [Related]

  • 13. Clinical and molecular characterization of a cardiac ryanodine receptor founder mutation causing catecholaminergic polymorphic ventricular tachycardia.
    Wangüemert F, Bosch Calero C, Pérez C, Campuzano O, Beltran-Alvarez P, Scornik FS, Iglesias A, Berne P, Allegue C, Ruiz Hernandez PM, Brugada J, Pérez GJ, Brugada R.
    Heart Rhythm; 2015 Jul 24; 12(7):1636-43. PubMed ID: 25814417
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. A novel mutation in FKBP12.6 binding region of the human cardiac ryanodine receptor gene (R2401H) in a Japanese patient with catecholaminergic polymorphic ventricular tachycardia.
    Aizawa Y, Ueda K, Komura S, Washizuka T, Chinushi M, Inagaki N, Matsumoto Y, Hayashi T, Takahashi M, Nakano N, Yasunami M, Kimura A, Hiraoka M, Aizawa Y.
    Int J Cardiol; 2005 Mar 18; 99(2):343-5. PubMed ID: 15749201
    [Abstract] [Full Text] [Related]

  • 17. The role of stress test for predicting genetic mutations and future cardiac events in asymptomatic relatives of catecholaminergic polymorphic ventricular tachycardia probands.
    Hayashi M, Denjoy I, Hayashi M, Extramiana F, Maltret A, Roux-Buisson N, Lupoglazoff JM, Klug D, Maury P, Messali A, Guicheney P, Leenhardt A.
    Europace; 2012 Sep 18; 14(9):1344-51. PubMed ID: 22383456
    [Abstract] [Full Text] [Related]

  • 18. A novel mutation in the RYR2 gene leading to catecholaminergic polymorphic ventricular tachycardia and paroxysmal atrial fibrillation: dose-dependent arrhythmia-event suppression by β-blocker therapy.
    Kazemian P, Gollob MH, Pantano A, Oudit GY.
    Can J Cardiol; 2011 Sep 18; 27(6):870.e7-10. PubMed ID: 21652165
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 31.